Skip to main content

Table 1 Patient characteristics of the intent-to-treat populationa

From: Repeated treatment of recurrent uncomplicated Plasmodium falciparum malaria in Senegal with fixed-dose artesunate plus amodiaquine versus fixed-dose artemether plus lumefantrine: a randomized, open-label trial

Characteristic

ASAQ

(n = 184)

AL

(n = 182)

p-value

Sex, n (%)

   

   Male

102 (55.4)

98 (53.8)

0.76b

Age, years

   

   Mean ± SD

11.94 ± 10.52

11.75 ± 9.17

0.67c

   Range

0.8-65.0

1.2-60.0

 

<12 years, n (%)

101 (54.9)

100 (54.9)

0.99b

Weight, kg

   

   Mean ± SD

29.55 ± 16.11

31.08 ± 17.34

0.59c

   Range

9.0-89.0

7.6-77.2

 

BMI, kg/m2

   

   Mean ± SD

14.87 ± 3.11

14.99 ± 3.22

0.58c

   Range

10.0-29.7

9.8-27.4

 

Parasite density, asexual forms/μl

   

   Geometric mean

32383.9 ± 37362

31713.7 ± 37253

0.716c

   Range

1034-195764

1016-195837

 

Gametocyte carriers, n (%)

7 (3.8)

2 (1.1)

0.174d

Blood haemoglobin, g/dL

   

   Mean ± SD

10.9 ± 2.3

10.8 ± 2.5

0.85e

   Range

5.8-15.8

5.5-18.2

 
  1. aAll randomized patients receiving at least one dose of study drug (patients vomiting twice after receipt of first dose were excluded); bChi2 test; cWilcoxon rank test; dFisher's exact test; eStudent t-test.